{
  "id": 26082,
  "title": "Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines",
  "url": "https://urgent.news/2026/07/30/takeda-regeneron-sanofi-and-bristol-myers-trim-pipelines",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-30T15:02:43.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/takeda-regeneron-sanofi-and-bristol-myers-squibb-trim-pipelines/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Biopharma earnings season is also pipeline update season. On Thursday, Takeda, Regeneron, Sanofi and Bristol Myers Squibb all announced program cuts as part of their quarterly updates. Some of the terminations were for early-stage programs: ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons",
        "url": "https://urgent.news/2026/07/30/regeneron-sanofi-tease-potential-expanded-collaboration-for-dupixent",
        "published": "2026-07-30T19:22:42.000Z"
      },
      {
        "outlet": "BioPharma Dive",
        "title": "Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs",
        "url": "https://urgent.news/2026/07/31/sanofi-to-rebuild-trust-with-regeneron-apnimed-adds-to-string-of",
        "published": "2026-07-31T15:06:47.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}